Beyond the App Store: What Digital-Health Intelligence Must Actually MeasureDigital health is often described as though its commercial problems were one of invention: building a useful app, connecting a device, applying artificial intelligence to a clinical question, and the market will follow. In practice, the difficult part begins after the product exists. A digital-health company may have credible clinical evidence, attractive user experience, and a plausible patient need, yet still struggle because it has not accounted for reimbursement, clinician workflow, procurement, health-system integration, data access, or the increasingly crowded field of adjacent competitors.That gap between technical promise and commercial reality is where market intelligence becomes more than a report-buying exercise. It becomes a discipline of deciding which facts matter, which signals are reliable, and which apparent opportunities can survive contact with a healthcare system that is fragmented by design.Market maps need operating contextA conventional market map can show the number of companies in a category, funding activity, leading geographies, and estimated revenue potential. Those are useful starting points, but they do not answer the more consequential question: under what conditions can a solution be adopted on scale? For digital health, the answer is rarely contained in a single data set.The World Health Organization has long made the point that digital health depends on standards for interoperability and data sharing, not simply on the availability of new tools. Its global strategy identifies syntactic and semantic interoperability as foundations for a connected health-information environment. For a company selling remote monitoring, virtual care, digital therapeutics, or patient-engagement software, that means the addressable market cannot be assessed solely by counting target patients or provider organizations. Navigating these complexities requires robust solutions, making intelligence around the Healthcare Interoperability Solutions Market and the standardization enforced by the Medical Terminology Software Market essential metrics for success.The ability to connect into existing clinical and administrative systems may be as decisive as the product’s headline capability. Roots Analysis’s competitive-intelligence portfolio is notable in this respect. The firm lists market sizing alongside voice-of-customer work, business-model assessment, competitor monitoring, product profiling, technology scouting, pricing analysis, regulatory-guideline monitoring, and channel-partner analysis. The breadth matters because these activities answer different versions of the same strategic question. Market sizing asks whether the opportunity may exist; customer research asks whether a problem is felt acutely enough to trigger a purchase; competitive monitoring asks who is already addressing it and how; pricing and reimbursement analysis test whether the apparent value can be translated into a commercial model.Adoption is a chain, not an eventDigital-health companies have sometimes treated adoption as a binary milestone: a hospital signs a contract, a payer includes a programmed, or a patient downloads an application. Healthcare buyers know that adoption is normally a chain of events. A clinician needs to understand the tool, the organization needs to configure it, data must move securely, a workflow must change, and someone must absorb the financial and operational burden.The result is that seemingly similar competitors can have radically different strategic positions. One may be winning because it is deeply embedded in the Electronic Health Records Market infrastructure, while another leverages mobility through the Wireless Electronic Health Records Market to capture point-of-care utility. A third may be acquiring users through direct-to-consumer marketing but lack a durable clinical distribution route.Treating those firms as interchangeable because they occupy the same broad category conceals more than it reveals. Roots Analysis’s published case study on a digital-therapeutics go-to-market engagement illustrates the sort of questions that matter. The firm says it developed a database of competitors segmented by company size and regional presence, then assessed marketing channels, business models, pricing approaches, end users, reimbursement focus, and digital features. Whether or not one generalizes from that specific engagement, the method is sound in principle: digital-health competition is not only about what a product does. It is about how it reaches users, who pays, which evidence is visible, and whether the path from interest to use contains too much friction.